Create a free account
Join Calaméo to publish and share documents with the world!
Rate and comment your favorite publications, download documents and share your readings with your friends.
Clinical Trial Endoints in Oncology
2 pages
Published by
rgunnam
Clinical Trial Endoints in Oncology - Inclusion of Surrogate Endpoints and Shorter
Endpoints will Ensure Faster Clinical Trials in Oncology
Survival – Primary Endpoint in Majority of the Market Products
The primary endpoint for the...
[More]
Clinical Trial Endoints in Oncology - Inclusion of Surrogate Endpoints and Shorter
Endpoints will Ensure Faster Clinical Trials in Oncology
Survival – Primary Endpoint in Majority of the Market Products
The primary endpoint for the approval of drugs in the oncology markets, which included
colorectal, ovarian, head, neck and prostate cancer, was survival.
The other endpoints in
these markets were response rate (complete, partial, objective, overall response rate and
so on).
The major marketed drugs approved after 1990 in the colorectal cancer market
were Camptosar (irinotecan), Xeloda (capecitabine), Avastin (Bevacizumab), Erbitux
(cetuximab), Vectibix (panitumumab) and Eloxatin (oxaliplatin).
The primary endpoint in
all these drugs was survival, followed by median time to tumor progression, tumor
response rate, progression-free survival, overall response rate and duration of response.
In
the prostate cancer market, the major marketed products were Taxotere (docetaxel),
Casodex (Bic
[Less]
Tags
analysis,
cancer,
clinical,
drugs,
endpoints,
included,
major,
market,
marketed,
oncology,
primary,
progression,
rate,
report,
response,
survival,
trials
